Loading…
PTC Therapeutics, Inc. is projected to rise to $110.94 by 2027, a +32% move from its current price of $84.20. PTCT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $82.23 | $84.25 | $86.31 | +0.05% |
| Jul 14 | $81.46 | $84.29 | $87.22 | +0.11% |
| Jul 15 | $80.88 | $84.34 | $87.94 | +0.16% |
| Jul 16 | $80.40 | $84.38 | $88.56 | +0.22% |
| Jul 17 | $79.98 | $84.43 | $89.12 | +0.27% |
| Jul 18 | $79.61 | $84.47 | $89.63 | +0.32% |
| Jul 19 | $79.28 | $84.52 | $90.10 | +0.38% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $79.28 | $84.52 | $90.10 | +0.38% |
| Week 2 | $77.50 | $84.84 | $92.87 | +0.76% |
| Week 3 | $76.22 | $85.16 | $95.14 | +1.14% |
| Week 4 | $75.21 | $85.48 | $97.15 | +1.52% |
| Week 5 | $74.36 | $85.80 | $99.00 | +1.90% |
| Week 6 | $73.63 | $86.13 | $100.74 | +2.29% |
| Week 7 | $72.99 | $86.45 | $102.40 | +2.67% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
PTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of medicines for children and adults living with rare disorders in the United States and internationally. Its portfolio includes therapies for Duchenne muscular dystrophy, AADC deficiency, rare diseases, and spinal muscular atrophy, with Upstaza marketed as Kebilidi in the United States.
Incorporated in 1998 and headquartered in Warren, New Jersey, the company distributes its products through third-party distributors and maintains collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. It also has a license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop the PTC518 Huntington's disease program, and its development pipeline includes Sepiapterin, PTC518, and vatiquinone among others.
PTC Therapeutics, Inc. trades as PTCT with a current price of $84.51 and a market capitalization of $7.01B. Its market rank is 1138. The stock’s near-term outlook appears bullish with a technical backdrop that supports a constructive path ahead.
The stock’s price action sits near key levels, with a resistance at $84.51 and a support level at $67.65. The market’s volatility is notable, reflecting a wide 30-day range and a robust momentum backdrop that aligns with a bullish longer-term view.
A major floor 29.3% below — a decisive break under it would weaken the trend.
The nearest floor, 19.0% below — buyers have tended to step in here.
The nearest ceiling, 6.4% above — a clean break opens room to run.
A major ceiling 21.4% above — clearing it would confirm fresh momentum.
Key PTCT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PTCT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $87.52 | Sell | $86.59 | Sell |
| MA 10 | $84.98 | Sell | $85.21 | Sell |
| MA 20 | $81.96 | Buy | $82.30 | Buy |
| MA 50 | $74.85 | Buy | $77.22 | Buy |
| MA 100 | $71.51 | Buy | $74.01 | Buy |
| MA 200 | $72.05 | Buy | $69.76 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 59.09 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 52.35 | Neutral |
| Williams %R (14) | -54.71 | Info |
| MACD (12,26,9) | 0.27 | Buy |
| ROC (12) | 3.31 | Buy |
| Bollinger %B (20,2) | 0.66 | Neutral |
| Stochastic %K (14) | 45.29 | Neutral |
| TRIX (15) | 0.67 | Buy |
| Awesome (5,34) | 10.13 | Buy |
| Ultimate (7,14,28) | 61.86 | Neutral |
| Momentum (10) | 0.34 | Buy |
| Aroon Osc (25) | 96.00 | Buy |
| Hull MA (9) | 89.66 | Sell |
| ADX (14) | 27.54 | Buy |
| ATR (14) | 1.77 | Info |
The 30-day technical picture shows bullish sentiment with RSI(14) at 70, indicating strong momentum. The price is trading above both the 50-day and 200-day simple moving averages, with SMA50 at $72.01 and SMA200 at $70.81.
Over the last 30 days, the range has been $71.85 to $99.40, with a key support at $67.65 and resistance at $84.51. These levels provide near-term guidance around the current price area.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $62.82 | $84.20 | $114.18 | 0% | Neutral | |
| $89.25 | $110.94 | $145.30 | +32% | Bullish | |
| $103.70 | $132.08 | $178.83 | +57% | Bullish | |
| $115.89 | $150.61 | $209.31 | +79% | Bullish | |
| $124.50 | $164.70 | $234.00 | +96% | Bullish | |
| $151.39 | $203.52 | $294.78 | +142% | Bullish | |
| $186.24 | $254.17 | $374.56 | +202% | Bullish | |
| $214.47 | $296.82 | $444.35 | +253% | Bullish | |
| $243.53 | $341.55 | $518.76 | +306% | Bullish | |
| $252.08 | $358.07 | $551.21 | +325% | Bullish | |
| $448.81 | $675.08 | $1,099.69 | +702% | Bullish | |
| $775.09 | $1,284.93 | $2,274.05 | +14.3x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $62.82 | $84.20 | $103.09 | +0.00% |
| August 2026 | $74.29 | $87.43 | $105.47 | +3.83% |
| September 2026 | $74.69 | $88.44 | $107.75 | +1.16% |
| October 2026 | $76.95 | $91.61 | $112.54 | +3.58% |
| November 2026 | $77.46 | $92.62 | $114.57 | +1.11% |
| December 2026 | $76.38 | $91.71 | $114.18 | -0.98% |
Click any year to see its month-by-month PTCT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect PTCT to range from $62.82 to $114.18 through 2026. The $84.20 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The PTCT price prediction for 2027 points to an average of $110.94 (low $89.25, high $145.30) — a potential gain of +32% on today's $84.20. Buyers look set to stay in control over this stretch.
In 2028, PTCT is projected to trade between $103.70 and $178.83, averaging $132.08 — a potential gain of +57% from today's $84.20. That is up +19% on the projected 2027 average. Momentum favours further upside here.
PTC Therapeutics, Inc.'s 2029 outlook centres on $150.61, within a $115.89 to $209.31 range. That is up +14% on the projected 2028 average. That marks a +79% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, PTCT could reach as high as $234.00, with a base case around $164.70 and support toward $124.50 — roughly +96% from $84.20. Momentum favours further upside here.
Expect PTCT to range from $151.39 to $294.78 through 2031. The $203.52 average target implies a +142% move from current prices. That is up +24% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The PTCT price prediction for 2032 points to an average of $254.17 (low $186.24, high $374.56) — a potential gain of +202% on today's $84.20. Momentum favours further upside here.
In 2033, PTCT is projected to trade between $214.47 and $444.35, averaging $296.82 — a potential gain of +253% from today's $84.20. That is up +17% on the projected 2032 average. Buyers look set to stay in control over this stretch.
PTC Therapeutics, Inc.'s 2034 outlook centres on $341.55, within a $243.53 to $518.76 range. That is up +15% on the projected 2033 average. That marks a +306% change versus current levels. Momentum favours further upside here.
By 2035, PTCT could reach as high as $551.21, with a base case around $358.07 and support toward $252.08 — roughly +325% from $84.20. Buyers look set to stay in control over this stretch.
Expect PTCT to range from $448.81 to $1,099.69 through 2040. The $675.08 average target implies a +702% move from current prices. That is up +89% on the projected 2035 average. Momentum favours further upside here.
The PTCT price prediction for 2050 points to an average of $1,284.93 (low $775.09, high $2,274.05) — a potential gain of +14.3x on today's $84.20. Buyers look set to stay in control over this stretch.
Investing $1,000 in PTCT today (≈ 11.876485 PTCT) could be worth
$15,260.4
+$14,260.4 (+1426%) by 2050 · US Dollar
Based on the average projected PTCT price of $1,284.93 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PTCTwould be worth at today's price.
$1,000 invested in PTCT on Jul 10, 2025 (≈ 20.193861 PTCT) would be worth
$1,700.32
+$700.32 (+70.0%) today · 1.70× · US Dollar
Based on a PTCT entry price of $49.52 vs. today's $84.2.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $83.31 | $1,010.68 | +1.1% |
| 1 month ago | $73.35 | $1,147.92 | +14.8% |
| 3 months ago | $68.69 | $1,225.8 | +22.6% |
| 6 months ago | $77.59 | $1,085.19 | +8.5% |
| 1 year ago | $49.52 | $1,700.32 | +70.0% |
| All time (5.0y) ago | $43.42 | $1,939.2 | +93.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PTCT forecast.
Our base-case forecast reaches $170.00 around 2031.
Implied market cap at $170.00: $14.1B
The multi-year forecast projects meaningful upside, led by strong avg prices in later years and double-digit ROI growth. For 2030 the avg is $157.54 with a max of $224.76 and an ROI of 86.4%, continuing a bullish trend through 2031–2035 before accelerating further.
In 2040 the forecast shows an avg of $585.19 with a min of $386.73 and a max of $958.57, delivering an ROI of 592.5% and reinforcing a bullish outlook.
By 2050 the forecast envisions an avg of $1,092.58 with a min of $653.60 and a max of $1,946.13, corresponding to an ROI of 1192.8% and a sustained bullish stance. These are estimates and not guarantees, and outcomes depend on market dynamics and other risks.
Tap a question to reveal the answer.
The forecast shows an average price of $157.54 in 2030, with a low of $118.68 and a high of $224.76, and a predicted ROI of 86.4%.
The long-term outlook is bullish, with rising average prices and substantial upside projected by 2030, 2040, and 2050. However, these are estimates, not guarantees, and depend on market conditions.
Yes. The forecast projects a 2029 max of $200.25 and a 2030 max of $224.76, indicating it can surpass $200 under the modeled scenarios.
PTCT’s current price is $84.51 and its market capitalization is $7.01B.
The 2040 forecast shows an average price of $585.19, with a low of $386.73 and a high of $958.57, and an ROI of 592.5%.
PTC Therapeutics, Inc. Community Discussion
0Share your PTC Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.